Human immunodeficiency virus protease inhibitors From drug design to clinical studies
- 15 September 1997
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 27 (2-3), 215-233
- https://doi.org/10.1016/s0169-409x(97)00044-6
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugsPharmacological Research, 1995
- Clinical Pharmacokinetics Of Nucleoside Antiretroviral AgentsThe Journal of Infectious Diseases, 1995
- Reduction Of The In Vitro Activity Of A77003, An Inhibitor Of Human Immunodeficiency Virus Protease, By Human Serum 1 Acid GlycoproteinThe Journal of Infectious Diseases, 1995
- Inhibitors of HIV proteinaseExpert Opinion on Investigational Drugs, 1994
- ZidovudineDrugs, 1993
- STRUCTURE-BASED INHIBITORS OF HIV-1 PROTEASEAnnual Review of Biochemistry, 1993
- Pharmacokinetic Drug Interactions with RifampicinClinical Pharmacokinetics, 1992
- ZidovudineDrugs, 1989
- Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtainedin vitro as well as on physiological dataJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearanceJournal of Pharmacokinetics and Biopharmaceutics, 1977